Tovinontrine
Tier C — Watch / tradeTovinontrine
Targets：PDE9A
Indications (approved)：Systolic heart failure, Diastolic heart failure, Heart disease, Heart failure, Sickle cell disease, Beta thalassaemia, 血红蛋白SC病
Regional status
Synthetic routes & intermediates1 routes
Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.
| Code | CAS No. | Intermediate |
|---|---|---|
| IMR-687-001 | 93102-05-7 | N-benzyl-1-methoxy-N-((trimethylsilyl)methyl)methanamine |
| IMR-687-002 | 623-70-1 | ethyl (E)-but-2-enoate |
| IMR-687-003 | 351370-91-7 | ethyl 1-benzyl-4-methylpyrrolidine-3-carboxylate |
| IMR-687-004 | 2062661-39-4 | ethyl (3S,4S)-1-benzyl-4-methylpyrrolidine-3-carboxylate |
| IMR-687-005 | 1434126-87-0 | 1-(tert-butyl) 3-ethyl (3S,4S)-4-methylpyrrolidine-1,3-dicarboxylate |
| IMR-687-006 | 1393524-21-4 | (3S,4S)-1-(tert-butoxycarbonyl)-4-methylpyrrolidine-3-carboxylic acid |
| IMR-687-007 | 2062661-44-1 | tert-butyl (3S,4S)-3-(methoxy(methyl)carbamoyl)-4-methylpyrrolidine-1-carboxylate |
| IMR-687-008 | 2062661-45-2 | tert-butyl (3S,4S)-3-acetyl-4-methylpyrrolidine-1-carboxylate |
| IMR-687-009 | 2062661-46-3 | tert-butyl (3S,4S)-3-(2-bromoacetyl)-4-methylpyrrolidine-1-carboxylate |
| IMR-687-010 | 883876-21-9 | methyl 2,4-dibromo-1H-imidazole-5-carboxylate |
| IMR-687-011 | 2062661-47-4 | methyl 2,4-dibromo-1-(2-((3S,4S)-1-(tert-butoxycarbonyl)-4-methylpyrrolidin-3-yl)-2-oxoethyl)-1H-imidazole-5-carboxylate |
| IMR-687-012 | 2062661-48-5 | ert-butyl (3S,4S)-3-(1,3-dibromo-8-oxo-7,8-dihydroimidazo[1,5-a]pyrazin-6-yl)-4-methylpyrrolidine-1-carboxylate |
| IMR-687-013 | 287944-16-5 | 2-(3,6-dihydro-2H-pyran-4-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane |
| IMR-687-014 | 2062661-49-6 | tert-butyl (3S,4S)-3-(1-bromo-3-(3,6-dihydro-2H-pyran-4-yl)-8-oxo-7,8-dihydroimidazo[1,5-a]pyrazin-6-yl)-4-methylpyrrolidine-1-carboxylate |
| IMR-687-015 | 2062661-50-9 | tert-butyl (3S,4S)-3-methyl-4-(8-oxo-3-(tetrahydro-2H-pyran-4-yl)-7,8-dihydroimidazo[1,5-a]pyrazin-6-yl)pyrrolidine-1-carboxylate |
| IMR-687-016 | 2062661-52-1 | 6-((3S,4S)-4-methylpyrrolidin-3-yl)-3-(tetrahydro-2H-pyran-4-yl)imidazo[1,5-a]pyrazin-8(7H)-one hydrochloride |
| IMR-687-017 | 54198-88-8 | 2-(chloromethyl)pyrimidine |
| IMR-687-018 | 1072-84-0 | 1H-imidazole-5-carboxylic acid |
| IMR-687-019 | 17325-26-7 | methyl 1H-imidazole-5-carboxylate |
Frequently asked questions
What are the approved indications of Tovinontrine?
Approved indications include: Systolic heart failure, Diastolic heart failure, Heart disease, Heart failure, Sickle cell disease, Beta thalassaemia, 血红蛋白SC病.
When does the Tovinontrine patent expire?
No public expiry year is available for Tovinontrine yet; this page updates once verified.
How many synthesis routes are recorded for Tovinontrine?
1 synthesis routes are recorded; the shortest is 15 steps with 580 mg (IMR-687) total yield. Intermediates in each route carry codes and CAS numbers.
Where can I buy Tovinontrine intermediates?
All intermediates in Tovinontrine routes have CAS profiles — you can submit an RFQ per CAS and it enters the Unibest matching pool.
How do I get a quote for Tovinontrine intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-09